The effects of remimazolam combined with sufentanil on respiration, circulation and sedation level in patients undergoing colonoscopy.
Colonoscopy
Propofol
Remimazolam
Sedation
Sufentanil
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
09
08
2023
accepted:
17
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
The main sedative which is propofol in painless gastroenteroscopy, has a high risk of reducing blood pressure and respiratory depression. Remimazolam (a short-acting benzodiazepine) is expected to be widely used in painless gastroenteroscopy due to its rapid onset, rapid metabolism and light respiratory and circulation inhibition. A randomized, single-blind, parallel, controlled study, 123 outpatients who were undergoing painless colonoscopy and ramdomly divided into group A, B and C, in Hangzhou First People's Hospital, July-December 2021. All patients were intravenously injected with 5 µg sufentanil for analgesic preconditioning. The group A was induced by 0.2 mg/kg remimazolam besylate. The group B was induced by 0.25 mg/kg remimazolam besylate. And the group C was inducted by 2.0 mg /kg propofol. If the patients had limb movement or MOAA/S score > 3 and so on, remimazolam besylate was added at 2.5 mg/ time in group A and B, and propofol emulsion injection was added at 0.5 mg/kg/ time in group C. During the operation, according to the actual situation, remimazolam was per added 2.5 mg in the experimental group, and propofol was 0.5 mg/kg in the control group. Heart rate (HR), non-invasive blood pressure (BP), respiratory rate (RR), pulse oxygen saturation (SpO The successful rate of induction in three groups was 100%. There was no significant difference in the sedation completion rate among the three groups (Group A:90.2%, Group B: 92.7%, Group C: 92.7%, P = 1.000). The rate of adverse events after administration: group A(27.0%) and B(36.8%) both lower than group C(71.0%),P < 0.001;There was no significant difference between group A and group B, P > 0.744;The average time from the last drug administration to meet the discharge criteria of the subjects in three groups was as follows: The average time of group A(16.2 min) and Group B(16.5 min) both shorter than group C(19.6 min), P = 0.001; There was no significant difference between group A and group B, P = 0.742. This study revealed that remimazolam is a safe and effective medication for colonoscopy sedation, the security of remimazolam is better than propofol, and the sedative effect with the initial dose of 0.25 mg/kg of remimazolam is optimal. China Clinical Trial Center with registration number: 2100052615,02/11/2021.
Sections du résumé
BACKGROUND
BACKGROUND
The main sedative which is propofol in painless gastroenteroscopy, has a high risk of reducing blood pressure and respiratory depression. Remimazolam (a short-acting benzodiazepine) is expected to be widely used in painless gastroenteroscopy due to its rapid onset, rapid metabolism and light respiratory and circulation inhibition.
METHODS
METHODS
A randomized, single-blind, parallel, controlled study, 123 outpatients who were undergoing painless colonoscopy and ramdomly divided into group A, B and C, in Hangzhou First People's Hospital, July-December 2021. All patients were intravenously injected with 5 µg sufentanil for analgesic preconditioning. The group A was induced by 0.2 mg/kg remimazolam besylate. The group B was induced by 0.25 mg/kg remimazolam besylate. And the group C was inducted by 2.0 mg /kg propofol. If the patients had limb movement or MOAA/S score > 3 and so on, remimazolam besylate was added at 2.5 mg/ time in group A and B, and propofol emulsion injection was added at 0.5 mg/kg/ time in group C. During the operation, according to the actual situation, remimazolam was per added 2.5 mg in the experimental group, and propofol was 0.5 mg/kg in the control group. Heart rate (HR), non-invasive blood pressure (BP), respiratory rate (RR), pulse oxygen saturation (SpO
RESULTS
RESULTS
The successful rate of induction in three groups was 100%. There was no significant difference in the sedation completion rate among the three groups (Group A:90.2%, Group B: 92.7%, Group C: 92.7%, P = 1.000). The rate of adverse events after administration: group A(27.0%) and B(36.8%) both lower than group C(71.0%),P < 0.001;There was no significant difference between group A and group B, P > 0.744;The average time from the last drug administration to meet the discharge criteria of the subjects in three groups was as follows: The average time of group A(16.2 min) and Group B(16.5 min) both shorter than group C(19.6 min), P = 0.001; There was no significant difference between group A and group B, P = 0.742.
CONCLUSIONS
CONCLUSIONS
This study revealed that remimazolam is a safe and effective medication for colonoscopy sedation, the security of remimazolam is better than propofol, and the sedative effect with the initial dose of 0.25 mg/kg of remimazolam is optimal.
TRIAL REGISTRATION
BACKGROUND
China Clinical Trial Center with registration number: 2100052615,02/11/2021.
Identifiants
pubmed: 39054423
doi: 10.1186/s12871-024-02644-0
pii: 10.1186/s12871-024-02644-0
doi:
Substances chimiques
remimazolam
7V4A8U16MB
Hypnotics and Sedatives
0
Benzodiazepines
12794-10-4
Sufentanil
AFE2YW0IIZ
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
252Informations de copyright
© 2024. The Author(s).
Références
Fu YH, Yang YH, He JH. Research progress of clinical application of colonoscopy. Clin Med Res Pract. 2021;6(30):189–91.
Cao B, Tao F, Cheng XX, et al. Clinical study on the safety of painless colonoscopy (report of 1700 cases). China J Endoscopy. 2011;17(11):1196–200.
Shirota Y, Hirase Y, Suda T, Miyazawa M, Hodo Y, Wakabayashi T. More than half of hypoxemia cases occurred during the recovery period after completion of esophagogastroduodenoscopy with planned moderate sedation. Sci Rep. 2020;10(1):4312.
doi: 10.1038/s41598-020-61120-0
pubmed: 32152344
pmcid: 7063059
Sneyd JR, Absalom AR, Barends CRM, Jones JB. Hypotension during propofol sedation for colonoscopy: a retrospective exploratory analysis and meta-analysis. Br J Anaesth. 2022;128(4):610–22.
doi: 10.1016/j.bja.2021.10.044
pubmed: 34916051
Dossa F, Medeiros B, Keng C, Acuna SA, Baxter NN. Propofol versus midazolam with or without short-acting opioids for sedation in colonoscopy: a systematic review and meta-analysis of safety, satisfaction, and efficiency outcomes. Gastrointest Endosc. 2020;91(5):1015–26. e7.
doi: 10.1016/j.gie.2019.12.047
pubmed: 31926966
Sipe BW, Rex DK, Latinovich D, Overley C, Kinser K, Bratcher L, et al. Propofol versus midazolam/meperidine for outpatient colonoscopy: administration by nurses supervised by endoscopists. Gastrointest Endosc. 2002;55(7):815–25.
doi: 10.1067/mge.2002.124636
pubmed: 12024134
Ulmer BJ, Hansen JJ, Overley CA, Symms MR, Chadalawada V, Liangpunsakul S, et al. Propofol versus midazolam/fentanyl for outpatient colonoscopy: administration by nurses supervised by endoscopists. Clin Gastroenterol Hepatol. 2003;1(6):425–32.
doi: 10.1016/S1542-3565(03)00226-X
pubmed: 15017641
Chen D, Taylor KP, Hall Q, Kaplan JM. The neuropeptides FLP-2 and PDF-1 act in Concert to arouse Caenorhabditis elegans Locomotion. Genetics. 2016;204(3):1151–9.
doi: 10.1534/genetics.116.192898
pubmed: 27585848
pmcid: 5105848
Cornett EM, Novitch MB, Brunk AJ, Davidson KS, Menard BL, Urman RD, et al. New benzodiazepines for sedation. Best Pract Res Clin Anaesthesiol. 2018;32(2):149–64.
doi: 10.1016/j.bpa.2018.06.007
pubmed: 30322456
Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107(1):60–6.
doi: 10.1097/01.anes.0000267503.85085.c0
pubmed: 17585216
Upton RN, Somogyi AA, Martinez AM, Colvill J, Grant C. Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. Br J Anaesth. 2010;105(6):798–809.
doi: 10.1093/bja/aeq260
pubmed: 20926479
Eisenried A, Schuttler J, Lerch M, Ihmsen H, Jeleazcov C. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of Electroencephalogram effects. Anesthesiology. 2020;132(4):652–66.
doi: 10.1097/ALN.0000000000003102
pubmed: 31972657
Schuttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020;132(4):636–51.
doi: 10.1097/ALN.0000000000003103
pubmed: 31972655
Rex DK, Bhandari R, Lorch DG, Meyers M, Schippers F, Bernstein D. Safety and efficacy of remimazolam in high risk colonoscopy: a randomized trial. Dig Liver Dis. 2021;53(1):94–101.
doi: 10.1016/j.dld.2020.10.039
pubmed: 33243567
Chen SH, Yuan TM, Zhang J, Bai H, Tian M, Pan CX, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol. 2021;36(2):474–81.
doi: 10.1111/jgh.15188
pubmed: 32677707
Chen X, Sang N, Song K, Zhong W, Wang H, Jiang J, et al. Psychomotor recovery following remimazolam-induced sedation and the effectiveness of Flumazenil as an antidote. Clin Ther. 2020;42(4):614–24.
doi: 10.1016/j.clinthera.2020.02.006
pubmed: 32178858
Wu HX, Chen T, Chen JL, et al. Effect of low-dose etomidate pretreatment on propofol injection pain. Fujian Med J. 2021;43(05):61–4.
Chinese expert consensus. On sedation/anesthesia for digestive endoscopy. J Clin Anesthesiol. 2014(09):920–7.
Expert consensus on. Anesthesia management for common digestive endoscopic surgery. Chin J Dig Endoscopy. 2019(01):9–19.
Han X, Guo YH, Shi XD, Zhang XL. Interpretation of Chinese Guideline for Bowel Preparation for Coloniscopy (2019). Clin Focus. 2020;35(01):72–5.
Saari TI, Uusi-Oukari M, Ahonen J, Olkkola KT. Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev. 2011;63(1):243–67.
doi: 10.1124/pr.110.002717
pubmed: 21245208
Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34(4):543–53.
doi: 10.1007/s00540-020-02788-6
pubmed: 32417976
Chen S, Wang J, Xu X, Huang Y, Xue S, Wu A, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Translational Res. 2020;12(8):4594–603.
Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88(3):427–e376.
doi: 10.1016/j.gie.2018.04.2351
pubmed: 29723512
Deng XM. Modern Anesthesiology. 4th Ed. Modern Anesthesiology. 4th Ed; 2014.
Sneyd JR, Absalom AR, Barends CRM, Jones JB. Hypotension during propofol sedation for colonoscopy: a retrospective exploratory analysis and meta-analysis. British journal of anaesthesia. 2022;128(4):610-22
Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems. Br J Pharmacol. 2008;155(1):52–61.
doi: 10.1038/bjp.2008.228
pubmed: 18552878
pmcid: 2527850
Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. Br J Anaesth. 2009;103(6):848–57.
doi: 10.1093/bja/aep269
pubmed: 19797247
Schüttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020;132(4):636–51.
doi: 10.1097/ALN.0000000000003103
pubmed: 31972655
Cardia L. Remimazolam: an ultrashort-acting intravenous anesthetic suitable for general anesthesia. Minerva Anestesiol. 2021;87(10):1059–63.
doi: 10.23736/S0375-9393.21.16006-7
pubmed: 34337928